soul trial oral semaglutide cardiovascular outcomes results 2024 2025 SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

22.89

★★★★☆4.8 (126)

An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25

28.31

★★★★★4.9 (98)

Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial

25.94

★★★★★5.0 (157)

Congreso ACC. 25: Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

24.57

★★★★★4.7 (84)

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

26.58

★★★★★4.9 (203)

Projected impact of oral semaglutide on cardiovascular outcomes over

27.75

★★★★★5.0 (176)

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

23.23

★★★★★4.8 (132)